Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...

Related Keywords

United States ,China ,California ,San Diego ,Japan ,Canada ,Los Angeles ,Mark Pimentel ,Mark Pimental ,Fosun Pharma ,Prnewswire Ardelyx Inc ,Ardelyx Inc ,Nasdaq ,Cedars Sinai Medical Center ,Disease Week Conference ,Poster Presentations ,Term Treatment ,Tenapanor Improves Abdominal Pain ,Treatment Satisfaction ,Irritable Bowel Syndrome ,Early Onset ,Treating Symptoms ,Product Theater ,Innovative Approach ,Brooks Cash ,Lillie Sterling Professor ,Science Center ,Houston Mcgovern Medical School ,Executive Director ,Medically Associated Science ,Medical Center ,Serious Dehydration ,Prescribing Information ,Boxed Warning ,Kyowa Kirin ,Knight Therapeutics ,